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Pleiotropic action of CpG-ODN on 
endothelium and macrophages 
attenuates angiogenesis through 
distinct pathways
Jiahui Wu1, Wenru Su2,3, Michael B. Powner4, Jian Liu1, David A. Copland1, Marcus Fruttiger4, 
Paolo Madeddu5, Andrew D. Dick1,4,6 & Lei Liu1
There is an integral relationship between vascular cells and leukocytes in supporting healthy tissue 
homeostasis. Furthermore, activation of these two cellular components is key for tissue repair 
following injury. Toll-like receptors (TLRs) play a role in innate immunity defending the organism 
against infection, but their contribution to angiogenesis remains unclear. Here we used synthetic TLR9 
agonists, cytosine-phosphate-guanosine oligodeoxynucleotides (CpG-ODN), to investigate the role 
of TLR9 in vascular pathophysiology and identify potential therapeutic translation. We demonstrate 
that CpG-ODN stimulates inflammation yet inhibits angiogenesis. Regulation of angiogenesis by 
CpG-ODN is pervasive and tissue non-specific. Further, we noted that synthetic CpG-ODN requires 
backbone phosphorothioate but not TLR9 activation to render and maintain endothelial stalk cells 
quiescent. CpG-ODN pre-treated endothelial cells enhance macrophage migration but restrain pericyte 
mobilisation. CpG-ODN attenuation of angiogenesis, however, remains TLR9-dependent, as inhibition 
is lost in TLR9 deficient mice. Additionally, CpG-ODNs induce an M1 macrophage phenotype that 
restricts angiogenesis. The effects mediated by CpG-ODNs can therefore modulate both endothelial 
cells and macrophages through distinct pathways, providing potential therapeutic application in ocular 
vascular disease.
Angiogenesis is critical to physiological homeostasis, maintaining tissue health and supporting repair processes, 
such as wound healing and tissue regeneration. On the other hand, pathological angiogenesis occurs in disease 
situations, such as diabetes and cancer. Therefore, pharmacological control of angiogenesis represents a valuable 
therapeutic target for a wide spectrum of conditions. The process consists of multiple events, including initial 
disruption of vascular integrity (detachment of mural cells and extracellular matrix disruption), followed by 
a productive stage (proliferation, migration, sprouting, and tubing of vascular endothelial cells) and final sta-
bilisation (incorporation of vascular smooth muscle cells and pericytes) resulting in a functionally competent 
vascular network1,2. A spectrum of angiocrine factors and chemokines modulate the different stages of angio-
genesis3,4. Furthermore, recruitment of inflammatory and immune cells occurs in parallel, modifying and ampli-
fying the processes afforded by local vascular cells5. Macrophages contribute significantly within a multicellular 
environment to angiogenesis, in part through release of paracrine promoters of tissue repair, but also through 
pro-inflammatory factors6. For example, although not exclusively, M1 macrophage phenotype is considered 
pro-inflammatory, while M2 macrophages are associated with vascular healing7.
Toll-like receptors (TLRs) widely expressed in multiple tissues and cell types belong to the pattern recognition 
receptor family and function as part of the first line of defence in the innate immune system by detecting the 
presence of pathogens8. The roles of TLRs in inflammation have been reported in a large number of studies9,10. 
TLRs also regulate angiogenesis in a variety of inflammatory settings11. However, the TLRs are pleomorphic 
1Academic Unit of Ophthalmology, School of Clinical Sciences, University of Bristol, UK. 2State Key Laboratory 
of Ophthalmology, Zhongshan Ophthalmic Centre, Sun Yat-sen University, Guangzhou, China. 3Centre for Clinic 
Immunology, Sun Yat-sen University Third Affiliated Hospital, Guangzhou, China. 4UCL-Institute of Ophthalmology, 
University College London, London, UK. 5Bristol Heart Institute, School of Clinical Sciences, University of Bristol, UK. 
6National Institute for Health Research (NIHR) Biomedical Research Centre, Moorfields Eye Hospital, London, UK. 
Correspondence and requests for materials should be addressed to L.L. (email: lei.liu@bristol.ac.uk)
Received: 30 March 2016
Accepted: 26 July 2016
Published: 25 August 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:31873 | DOI: 10.1038/srep31873
Figure 1. Three classes of CpG-ODNs suppress angiogenesis differentially by regulating expression 
of VEGF and sFlt1. (a) Representative phase-contrast photos of mouse aortic rings show the angiogenic 
inhibition by CpG-ODNs at day 7. Scale bar: 500 μ m. Photos were taken under Wide field microscope (Leica 
DMI6000) with x5 magnification lens, each photo was composed of 4 images to represent one whole picture of 
each ring treated with 5 μ M CpG-ODNs. (b) The sprout number was counted under Leica SP5-AOBS confocal 
laser scanning microscope (x5) after whole mount immunofluorescent staining with anti-CD31-APC (1:100, 
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and functionally disparate, and the current study examined anti-angiogenic effects mediated by specific TLR9 
agonists, cytosine-phosphate-guanosine oligodeoxynucleotides (CpG-ODNs). CpG-ODNs have been shown to 
inhibit suture-induced mouse corneal neovascularization12, microvessel formation and tumour growth13, but 
whether these anti-angiogenic effects extends to other angiogenesis-related diseases and can offer therapeutic 
potential has not been fully explored. The effects mediated by CpG-ODNs is dependent on the number and 
location of CpG motifs, but also the backbone structure and length of the nucleotides14. As the natural ODN 
backbone phosphodiester (PD) is easily degraded by nucleases14, most of the current synthetic CpG-ODNs used 
in tumour clinical trials are phosphorothioate (PS)-modified to enhance stability14–16. These chemically modified 
synthetic CpG-ODNs are divided into three classes (class A, B and C) based on their sequence backbones and 
location of CpG motifs with distinct biological responses17. TLR9 expression is localised to intracellular mem-
branes and activated within the endolysosome. When unmethylated CpG motifs (derived from viral or bacterial 
DNA) is recognised by TLR9, activation engages adaptor protein MyD88 and NF-κ B to initiate an innate inflam-
matory response8. CpG-ODNs are synthetic TLR9 agonists and have been exploited as adjuvants for anti-tumour 
and vaccine therapeutics. CpG-ODN activation of TLR9 induces anti-tumour immunity and suppresses angio-
genesis in tumours12,18–22.
Following our initial findings12, the aim of this study was to refine our understanding of pathways utilised by 
the family of CpG-ODNs mediated anti-angiogenesis in ocular angiogenesis models. We demonstrate that the 3 
classes of CpG-ODN can each inhibit angiogenic responses in the eye, and their addition to endothelial cells pro-
motes macrophage trafficking but reduced pericytes mobilisation. Furthermore, we also show that suppression 
of endothelial cell activity by CpG-ODNs is dependent upon PS-modified backbone and is not TLR9-dependent. 
However, TLR9-dependent macrophage activation by CpG-ODNs was required to promote M1 phenotype and 
modulate angiogenesis through regulation of endothelial cell function.
Results
Three classes of CpG-ODNs suppress angiogenesis by differentially regulating expression of 
VEGF and sFlt1. Whilst the pro-inflammatory response induced by CpG-ODNs is recognised, these agents 
also modulate other functional effects, and we have previously demonstrated that ODN1826 can inhibit angio-
genesis12. To expand these observations, we investigated whether this anti-angiogenic effect was ubiquitous to 
all 3 classes of CpG-ODN. Initially, mouse aortic rings were treated with three classes of murine CpG-ODN and 
their non-CpG-ODN controls (in which the CpG motifs were replaced by GpC). All three classes of CpG-ODN 
(class A: ODN1585; class B: ODN1826; class C: ODN2395) and their internal controls suppressed the formation 
of aortic endothelial sprouts in a dose-dependent manner (Fig. 1a,b and supplementary Fig. S1a,b). Assessment 
of VEGF and sFlt1 proteins in explant supernatants revealed differential expression of these factors depending 
on the class of ODN present. Class A at all tested concentrations and class C only at the high dose (5 μ M) signif-
icantly decreased VEGF production (Fig. 1c). In contrast, class B and C at the high dose significantly increased 
sFlt1 production (Fig. 1d). Furthermore, in HUVEC tube formation assay, human class A (ODN2216) and class 
C (ODN2395) as well as their controls markedly suppressed HUVEC tube formation (Fig. 1e and Supplementary 
Fig. S1c).
Next, we tested all three classes of CpG-ODN and their non-CpG-ODN controls in vivo using the 
suture-induced corneal angiogenesis model. Class B and C inhibited corneal angiogenesis, showing a significant 
reduction in length and volume of blood and lymphatic vessels, whilst no effect was observed with class A or 
control ODN treatments (Fig. 1f–i and Supplementary Fig. S1d). Previously, no significant change in VEGF or 
sFlt-1 protein expression in cornea was detected following class B treatment12, and this was confirmed at the tran-
scriptional level (Supplementary Fig. S1e). In summary, all three classes of CpG-ODN inhibited aortic vascular 
sprouting but only class B and C CpG-ODNs suppressed corneal angiogenesis. We therefore focused on these 
two classes in the following experiments. Increased sFlt-1 secretion (aortic ring assay) and in vivo suppression of 
corneal neovascularisation support current evidence that expression of sFlt-1 in the normal cornea regulates vas-
cular growth23. Furthermore, class A failed to suppress corneal angiogenesis despite evidence of reduced VEGF 
expression, which suggests sFlt1 dominance as a pathway to suppress corneal angiogenesis.
ODNs regulate angiogenesis in a backbone dependent but CpG motif independent manner. 
TLR9 is widely expressed in endosomes in many different cell types11, and activation of the TLR9 signalling 
pathway is dependent on binding CpG-ODNs. However, the downstream activity of CpG-ODN signalling is 
n = 15–18 per condition). All three classes of CpG-ODNs (class A: ODN1585; class B: ODN1826; class C: 
ODN2395) suppressed aortic ring sprouts compared to medium control at a dose-dependent manner.  
(c,d) The VEGF production in the supernatant of aortic rings was decreased by both class A and class C 
CpG-ODNs, while both class B and class C CpG-ODNs increased the sFlt1 production in supernatant tested 
by ELISA. (e) Class A and C CpG-ODNs completely inhibited the HUVECs tube formation compared to 
medium control after 24 hours (n = 12 per condition). Scale bar, 500 μ m. (f) Upper row: Representative photos 
of suture-induced corneal angiogenesis model 7 days post sub-conjunctival administration of water or CpG-
ODNs. Lower row: flat mount immunofluorescent staining of sutured cornea with anti-CD31 (red, 1:100) and 
anti-LYVE1 antibodies (green, 1:200) (n = 18–20 per condition). Image capture was performed with Leica 
SP5 microscope (x20). Scale bar, 50 μ m. (g–i) Class B and class C but not class A CpG-ODN suppressed both 
hem- and lymph-angiogenesis in length and volume compared to vehicle control. Data represents means ± SD 
of relative values vs control from 3 independent experiments. * p < 0.05; * * p < 0.005; * * * p < 0.0005, statistical 
analysis was performed with one-way ANOVA with Dunn’s test.
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influenced by both the number of CpG-motifs and the structural backbone sequence17,24. In the current con-
text, it was important to determine whether the CpG motif and structure were central to elicit the observed 
anti-angiogenic effects. To this end, ODNs were customised as described in Supplementary Table S1: 
PD-CpG-ODN and PS-CpG-ODN share the same sequence motif but with different backbones; while 
PS-CpG-ODN and PS-ApG-ODN share same backbone but an altered sequence, in which the cytosine is replaced 
with adenine in CpG motifs.
When applied to aortic ring assay, alteration in sequence (PS-CpG-ODN and PS-ApG-ODN) still permit-
ted suppression of aortic sprouts but alteration in backbone (PD-CpG-ODN) lost the ability to suppress the 
explants irrespective of whether class B ODN1826 or class C ODN2395 (Fig. 2a,b). Both ODN classes when 
changing sequence of CpG motif (PS-CpG-ODNs or PS-ApG-ODNs) increased sFlt1 production, but only class 
C PS-CpG-ODNs and PS-ApG-ODNs decreased VEGF production (Fig. 2c,d). These findings indicate that 
PS-modified backbone is requisite for the anti-angiogenic process regulated through the ODN, but the CpG motif 
is dispensable. To confirm this, we selected and tested the customised class C ODN2395 in HUVECs, as it reacts 
with human and mouse cells. Consistent with aortic ring assay, both PS-CpG-ODN2395 and PS-ApG-ODN2395 
but not PD-CpG-ODN2395 suppressed tube formation (Supplementary Fig. S2a).
TLR9 activation is indispensable for suppressing angiogenesis through CpG-ODN in vivo but 
not required to suppress endothelial cells activity. While stimulation of cells with CpG motifs elicits 
TLR9 activation, our data suggested that specific motifs may be dispensable for enabling an anti-angiogenic 
response. Therefore, we wished to determine whether this also applied in vivo and whether TLR9 signal-
ling is indispensable for CpG-ODN mediated suppression of angiogenesis. Hence, PS-CpG-, PD-CpG- and 
PS-ApG-ODNs were tested in the suture induced corneal angiogenesis model. There was no inhibition of corneal 
neovascularisation when either the CpG motif or the PS backbone were individually substituted, and suppression 
was only observed in mice that received the PS-CpG-ODN (Fig. 3a–d), suggesting the structural CpG motif is 
Figure 2. ODN regulates angiogenesis in backbone dependent but CpG motif independent manner.  
(a,b) Representative phase contrast photos of aortic rings, 7 days after stimulation with PS-CpG-ODNs, PD-
CpG-ODNs, or PS-ApC-ODNs at the concentration of 5 μ M (n = 18–23 per condition). Scale bar, 500 μ m. Both 
PS-CpG-ODN and PS-ApG-ODN but not PD-CpG-ODN suppressed the aortic sprouts. (c,d) Both class B 
and C PS-CpG-ODNs and PS-ApG-ODNs increased sFlt1 production, whilst class C PS-CpG-ODNs and PS-
ApG-ODNs decreased VEGF production measured by ELISA of the supernatant. Data represents means ± SD 
of relative values vs control from 3 independent experiments. * p < 0.05; * * p < 0.005; * * * p < 0.0005, statistical 
analysis was performed with one-way ANOVA with Dunn’s test.
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Figure 3. TLR9 activation is indispensable for suppressing angiogenesis through CpG-ODN in vivo but 
not required in suppression of endothelial cell activity. (a) Flat mount CD31 (red, 1:100) and LYVE1 (green, 
1:200) immunofluorescent staining for sutured cornea 7 days post sub-conjunctival injection with class B and C 
CpG-ODNs as well as their customized controls (PD-CpG-ODN or PS-ApC-ODN) (n = 18–20 per condition). 
Images were captured using a confocal laser scanning microscope with x20 magnification lens. Scale bar, 50 μ m.  
(b–d) Only PS-CpG-ODNs suppressed the new vessels by reducing the length and volumes of both blood 
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essential to the anti-angiogenic response. The indispensable role of TLR9 signalling in vivo was further confirmed 
by experiments in which administration of ODN1826 in TLR9 deficient mice (TLR9−/−) did not suppress vessel 
growth (Fig. 3e,f).
To understand how TLR9 may regulate endothelial cell responses, we assessed the effect of blocking TLR9 
pathways in HUVECs. Chloroquine, a TLR9 activation inhibitor, is an endosomal acidification inhibitor which 
blocks TLR9 signalling, as acidic pH is a prerequisite for normal enodosomal TLR activation, but it also disrupts 
the binding of CpG motifs to TLR9 ectodomains25. PS-CpG-ODN2395 still suppressed endothelial tube for-
mation despite the presence of chloroquine (Fig. 3g). Furthermore, HUVEC tube formation was also inhibited 
following PS-CpG-ODN treatment when TLR9 gene expression was silenced using a siRNA approach (Fig. 3h). 
The efficacy of RNA interference on TLR9 expression was confirmed by PCR and western blot (Fig. 3i,j). The data 
indicates that intact TLR9 signalling is redundant for ODN-mediated suppression of HUVEC tube formation 
and the inhibition of endothelial activity. However, TLR9 signaling was indispensable in vivo, suggesting that 
CpG-ODN may inhibit angiogenesis through multiple cell types. We therefore wished to investigate whether the 
anti-angiogenic effect by CpG-ODNs is pervasive and/or tissue specific, with respect to ocular vasculature.
CpG-ODN suppresses retinal vessel formation and choroidal neovascularisation. As Class B 
(ODN1826) and Class C (ODN2395), but not Class A (ODN1585) suppress corneal angiogenesis, we investigated 
the B and C classes further to determine whether these observations conferred tissue specificity within the eye. 
During embryonic development, cells derived from the mesodermal and the ectodermal tissues contribute to the 
formation of the eye, with the neuroectoderm and mesoderm forming the retina and choroid respectively26–28. 
Firstly we examined whether local administration of CpG-ODNs influenced normal retinal vascular develop-
ment, and secondly, if these could also modulate wound healing responses in the choroid (another vascular com-
partment of the eye) following laser-photocoagulation29.
Mouse retinal vessels physiologically develop and reach the peripheral retina during the first week of life (P1-7), 
which permits assessment of post-natal vascular development. Following intravitreal administration of Class C 
to the eyes of P4 mice, the length of retinal vessel extension from the optic disc as well as the number of vascular 
tips were significantly reduced (Fig. 4a–d). Moreover, the area and volume of laser-CNV were also significantly 
reduced by both Class B and C (Fig. 4e–g). Consistent with these in vivo findings, Class B also suppressed the 
extent of choroidal sprouting and vascular proliferation in the choroidal explant assay (Fig. 4h,i). Together, the 
data supports that CpG-ODNs modulation of angiogenesis is neither tissue restricted nor reliant on an inciting 
event, such as wound healing in the laser-CNV model. Therefore, the next step was to understand whether the 
CpG-ODN mediated effects were indirect, and regulated pericyte and macrophage responses.
CpG-ODN inhibits endothelial migration and regulates the mobilization of pericytes and mac-
rophages. During angiogenesis, the activation of endothelial cells between stalk and tip cells is regulated by 
Notch and VEGF signalling pathways. The vascular supporting cells, pericytes and macrophages, facilitate the 
stabilisation and maturation of the angiogenic process. The anti-angiogenic effect on endothelial cells in vitro 
mediated by CpG-ODN alone does not suppress corneal neovascularisation in vivo, which led us to investigate 
how CpG-ODNs may affect the migratory ability of endothelial cells, pericytes and macrophages. Using the gap 
closure migration assay, ODN2395 significantly delayed the migration of HUVECs (Fig. 5a,b). We performed 
in vitro transwell experiments designed to assess the impact on migratory behaviour, in which human primary 
pericytes or bone-marrow derived macrophages (BMDM) were seeded in the upper chambers with conditioned 
medium from ODN2395 stimulated HUVECs. The addition of ODN2395 conditioned HUVEC supernatant sup-
pressed pericytes but accentuated macrophages migration, but the increase in macrophage migration was absent 
with ApG-ODN2395 conditioned supernatant (Fig. 5c,d). These results demonstrate the ability of CpG-ODN 
stimulated endothelial cells to restrain mobilization of pericytes yet promote macrophage migration in vitro.
CpG-ODN polarises macrophages toward an M1 phenotype and actively regulates angiogenesis. 
The current data shows that CpG-ODNs can enhance the migration of macrophages, which correlates with 
the previous observation of an increased number of infiltrating macrophages in sutured-cornea following 
CpG-ODN1826 administration12. The intrinsic plasticity of macrophages facilitates different functional responses 
depending on signals received in the tissue microenvironment30,31, and increasing evidence support the active 
regulatory role of macrophages in angiogenic processes32. To further interrogate whether the CpG-ODN medi-
ated suppression of angiogenesis was dependent on macrophage involvement, we depleted macrophages both 
and lymphatic vessels compared to vehicle control. (e,f) CpG-ODN1826 did not suppress suture-induced 
corneal neovascularisation in TLR9 deficient mice compared to water control, whilst ODN1826 significantly 
suppressed corneal angiogenesis in WT compared to TLR9 deficient mice (n = 6 per condition). (g) TLR9 
activation inhibitor chloroquine (100 nM) did not regulate HUVECs tube formation. CpG-ODN2395 still had 
anti-angiogenic effect on HUVECs in the presence of chloroquine (n = 12 per condition). Image capture was 
performed with Leica DMI6000 microscope (x 5). Scale bar, 500 μ m. (h) CpG-ODN2395 suppressed HUVEC 
tube formation despite TLR9 siRNA (10nM) transfection (n = 12 per condition). Scale bar: 500 μ m. (I,j) The 
efficacy of TLR9 siRNA in HUVECs were examined by conventional PCR and western blot with GAPDH and 
ß-actin as housekeeping controls. TLR9 production was reduced by 80.8% at transcriptional level and 69.7% 
at protein level. All the samples were normalized to their β -actin expressions. Data represents means ± SD of 
relative values vs control from 3 independent experiments. * p < 0.05; * * p < 0.005; * * * p < 0.0005, statistical 
analysis was performed with one-way ANOVA with Dunn’s test for multiple comparisons, while unpaired 
Student’s t test and Mann-Whitney test for two individual comparisons.
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Figure 4. CpG-ODN suppresses retinal vessel formation and choroidal neovascularisation. (a,b) Phase 
contrast photos (x2) of postnatal retina from P4 mice after being injected with either water or CpG-ODN2395 
(n = 6–8 per condition). CpG-ODN2395 suppressed the growth of retinal vessels. Images were taken under x10 
microscope lens. Scale bar, 1 mm. (c,d) Treated retinas from P4 mice were dissected for IB4 staining (1:100) 
for explant tips counting, CpG-ODN2395 reduced the number of tips in retinas. Scale bar, 200 μ m. (e,g) 
Intravitreal injection of CpG-ODN1826 immediately after laser photocoagulation in C57BL/6 mice reduced the 
area and volume of CNV at day 7 compared to water vehicle mice by evaluation of confocal images of choroid 
flat mount staining with anti-IB4 antibody (n = 18–22 per condition). Images were captured using a confocal 
laser scanning microscope with x20 microscope lens. The areas were quantified by Image J and volumes by 
Volocity. Scale bar, 50 μ m. (h,i) Phase contrast photos of mouse choroidal sprouts were taken after 7 days culture 
with or without CpG-ODNs (n = 23–25 per condition). All images were taken under Wide field microscope 
at x5 magnification for the measurement of sprouting areas. One photo was composed of several x5 images 
to show the whole area of explants. Scale bar, 500 μ m. CpG-ODN1826 suppressed the choroidal sprouts at 
concentration of 5 μ Μ compared to medium control. Data represents means ± SD of relative values vs control 
from 3 independent experiments. * p < 0.05; * * p < 0.005; * * * p < 0.0005, statistical analysis was performed with 
unpaired Student’s t test and Mann-Whitney test.
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systemically and locally by administration of clodronate liposomes. The efficacy of macrophage depletion system-
ically and locally (cornea and surrounding tissue) by clodronate was examined by immunohistochemistry stain-
ing of spleen and eye (Fig. 6a and Supplementary Fig. S3a,b). In the control (PBS liposomes) treated cornea, there 
was influx of myeloid cells with predominantly F4/80+ macrophages from limbus to mid-peripheral cornea post 
suturing. In contrast, only minimal infiltrating F4/80+ and CD11b+ cells were present in clodronate treated cor-
nea (Fig. 6a and Supplementary Fig. S3b). ODN1826 increased the number of corneal infiltrating macrophages 
in both PBS and clodronate treated mice, however, infiltration was still considerably lower in clodronate treated 
mice. Depletion of macrophages by clodronate was accompanied by reduction of corneal neovascularisation, 
although additional CpG-ODN did not augment this anti-angiogenic effect (Fig. 6b–e).
If macrophages are required in corneal neovascularisation and CpG-ODN augmented macrophages infil-
tration, we wished to further discern how CpG-ODN stimulated macrophages may regulate endothelial cell 
responses. The pre-conditioned culture supernatant from the macrophage cultures was added to HUVECs to 
assess tube formation. The excess of CpG-ODN was removed by changing to fresh medium after 8 h stimulation 
to minimize the direct effect of CpG-ODN. Only supernatants from CpG-ODN pre-conditioned macrophages 
were able to suppress HUVEC tubes (Fig. 6f–h). This suggested that CpG-ODN can stimulate macrophages to 
elicit mediators that directly modulate the angiogenic activity of endothelial cells.
We next explored whether CpG-ODN could polarise macrophages towards either an M1 or M2 phenotype. 
Accordingly, the responses of BMDM stimulated with CpG-ODN2395, ApG-ODN2395 or medium control for 
6 h and 24 h were analysed. LPS and IL-4 were included as stimuli controls for M1 and M2 polarization respec-
tively. CpG-ODN increased the mRNA expression of Nos2 and Tnfα, signatures of M1 activation33, but did not 
induce Arg1 expression of M2 activation (Fig. 6i–k)33. The control ApG-ODN did not upregulate any Nos2, Tnfα 
or Arg1 expression. In addition, none of the ODN treatments regulated transcriptional expression or protein 
Figure 5. CpG-ODN inhibits endothelial migration and regulates mobilization of pericytes and 
macrophages. (a) Representative phase contrast photos (x5) of gap closure migration assay with 5 μ Μ CpG-
ODN2395 at 0 h, 3 h and 6 h (n = 16 per condition). Scale bar, 500 μ m. (b) CpG-ODN2395 at concentration 
of 5 μ Μ delayed the HUVECs migration at 6 h by quantifying the area of the gaps. (c) Human pericytes were 
cultured in upper chamber of transwell with conditioned HUVECs medium or controls in lower chamber 
(n = 9–12 per condition). After 16 hours culture, the number of migrated pericytes were counted under Leica 
DMI6000 microscope (x20) after staining the membrane with DAPI. HUVECs culture medium (labelled 
control) promoted pericytes migration, but additional CpG-ODN2395 treatment suppressed the mobilisation 
of pericytes. (d) Similarly, transwell migration assay with mouse BMDM in upper chamber showed HUVECs 
culture medium promoted macrophages migration (n = 8–10 per condition). However, in contrast to pericytes, 
macrophages migration was significantly stimulated by CpG-ODN2395 but not by ApG-ODN2395. Data 
represents means ± SD of relative values vs control from 3 independent experiments. * p < 0.05; * * p < 0.005;  
* * * p < 0.0005, statistical analysis was performed with unpaired Student’s t test.
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Figure 6. CpG-ODN polarises macrophages to M1 phenotype which actively regulate angiogenesis.  
(a) Immunohistochemistry staining of F4/80 (1:100) showed macrophages influx was increased dramatically 
by CpG-ODN1826 in sutured cornea (n = 6–8 per condition). Clodronate restrained the significant reduced 
infiltrating macrophages at the limbus away from mid peripheral cornea of suture site with no recovery after 
CpG-ODN1826 treatment. Images were taken under x5 microscope lens. C: cornea; I: iris; L: limbus.  
(b–e) Corneal neovascularisation, both blood vessels (red) and lymphatic vessels (green), was significantly 
reduced in clodronate treated mice compared to PBS treated controls. CpG-ODN1826 did not induce any 
further reduction of either length or volumes of the neo-vessels (n = 16–18 per condition). Scale bar: 50 μ m. 
(f,h) After being stimulated with either CpG-ODN or ApG-ODN for 8 h, the supernatant of macrophages was 
replaced by fresh medium and leave for another 16 h culture before the supernatant was collected in 1:1 mix 
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levels of sFlt1 or Vegf in macrophages (Supplementary Fig. S3c,d). These results support that CpG-ODN polarises 
macrophage towards an M1 phenotype.
Discussion
The role of TLR9 in inflammation has long and widely been recognized34,35. More recently increasing studies 
haav demonstrated its role in angiogenesis21,36. We have previously shown that Class B CpG-ODN1826 sup-
presses corneal neovascularisation12. We now demonstrate the direct anti-angiogenic effect of CpG-ODNs on 
vascular endothelial cells independent of TLR9 signalling. TLR9 is indispensable for macrophage regulation of 
angiogenesis, as the effect is lost in the absence of CpG motif or in TLR9 deficient mice. The significance of the 
anti-angiogenic effect on multiple ocular disease models is the translational potential towards adjunct therapy for 
blinding angiogenic ocular disorders. Such therapeutic potential is further supported by the current assessment 
of TLR9 agonist CpG-ODN as vaccine adjuvants as a strategy in cancer research37. The current notion is that 
CpG-ODNs augment specific immune responses through TLR9 mediated NF-κ B activation, as well as CpG-ODN 
itself exhibits anti-tumour activity via reduction of VEGF and HIF-1α 38. Notwithstanding, it is evident from the 
data presented here that CpG-ODNs have wider actions that might offer exciting therapeutic exploitation, espe-
cially for ocular disorders where abnormal neovascularisation leads to blindness.
The anti-angiogenic effect of CpG-ODN within the eye is tissue nonspecific and pervasive as we observed 
attenuation of new vascular growth in a wide range of in vitro and in vivo models. Furthermore, all three classes 
of CpG-ODNs exhibited anti-angiogenic capacity, and predominantly through upregulation of sFlt-1. In aortic 
ring sprout assay, class A CpG-ODN suppressed VEGF secretion and class B stimulated sFlt1, whereas class C 
regulated both VEGF and sFlt1 (Fig. 1c,d). sFlt1 is a potent anti-angiogenic protein with high affinity to VEGF, 
and is highly upregulated by both class B and C ODNs corroborating the reduced VEGF secretion in aortic ring 
culture. Only class B and class C suppress corneal angiogenesis in vivo, which might be explained by the insta-
bility of the backbone of class A CpG-ODN compared to the other two classes14. To elucidate the mechanism 
by which CpG-ODNs may modulate angiogenesis, we demonstrate the influence of the ODN backbone. As the 
classes of ODNs not only differ in their number and location of CpG, but also the type of backbone, we custom-
ised class B and C ODNs with single nucleotide or backbone substitutions to the control ODNs. Both PS-ODNs 
with CpG or ApG, but not PD-ODN, displayed anti-angiogenic responses in aortic ring assay, suggesting that the 
PS backbone is responsible for inhibition of the aortic vascular sprouts, and sequence specificity is not requisite. 
We also observed reduced tube formation in HUVECs following ODN treatment, and again this was independent 
of either the ODN sequences or CpG motifs (Fig. 1e and Supplementary Fig. S2). It is recognized that in antisense 
biotechnology, one antisense oligonucleotide in theory may degrade or block its target RNAs, but that oligonucle-
otides may also have biological effects that are not attributable to their sequences39. Therefore, their effect on cel-
lular processes can be due to non-specific binding of oligonucleotides to proteins, or the reagents used to deliver 
the oligonucleotides. Many of the non-sequence-specific effects may be the result of the increased affinity of 
phosphorothioate ODN for binding proteins40. Phosphorothioate thymidine homopolymers, in contrast to other 
homopolymers, can induce the stimulation of human B cells or murine splenocytes41,42. The number of thymidine 
nucleobases in non-CpG phosphorothioate ODN, as well as the length of such ODN, directly relate to the mag-
nitude of their stimulatory effects43,44. Although phosphodiester (PD) is the natural backbone present in bacterial 
and viral DNAs, its use in synthetic ODNs is limited due to rapid degradation by the intracellular endonucleases 
and exonucleases45. In contrast, phosphothioates (PS) are widely used because of their nuclease stability and effi-
cient cellular uptake. Whilst an off-target effect on endothelial cells may contribute to anti-angiogeneic effects, it 
is not sufficient alone without TLR9 activation in vivo. To address the direct effect of CpG-ODN on endothelial 
cells, further data may identify the potential mechanisms driving off-target effects.
Angiogenesis requires VEGF-VEGFR2 signalling pathways. During sprouting, Dll4-Notch1 signalling 
selects the endothelial tip cells to lead the outgrowth of sprouts towards VEGF gradients46. To identify the 
anti-angiogenic effectors stimulated by ODNs in HUVECs and cornea, Vegf, Dll4, Notch1, and sFlt1 mRNAs 
were quantified. Among these, Dll4 and Notch1 were upregulated at 6 h in HUVECs (Supplementary Fig. S4). 
Dll4 is expressed in tip cells and acts on stalk cells to suppress stalk to tip cell conversion. Dll4 also binds to Notch 
receptors on neighbouring cells, and in turn downregulates VEGFR2 inhibiting endothelial cell proliferation47,48. 
The increased expression of Dll4 and Notch1 suggests that CpG-ODN maintains HUVECs at stalk cell status, 
a finding that is supported by the observation of unchanged level of Vegf and sFlt1 (Supplementary Fig. S4). 
Although no significant change of Dll4, Notch1, Vegf or sFlt1 mRNA expression was found in corneas after CpG 
ODN (Supplementary Fig. S1e), it is possible that these signals from tip cells localised at limbus in the multicellu-
lar responses were too weak to be detected in vivo. We also observed delayed development of retinal vasculature 
and reduced number of vascular tips by CpG-ODN during the first post-natal week in mice (Fig. 4a–d). However, 
with EGM for HUVECs tube formation assay (n = 16 per condition). Supernatant from CpG-ODN2395 but not 
ApG-ODN2395 treated macrophages reduced both the total length and junction number of tubes compared to 
control. Scale bar, 500 μ m. (i-k) BMDMs were cultured for 6 h or 24 h with stimulation of 5 μ M CpG-ODN2395, 
ApG-ODN2395 or medium alone as negative control. LPS (1 μ g/mL) and IL4 (20 U/mL) were used as positive 
controls for M1 and M2 macrophages polarization respectively (n = 12 per condition). CpG-ODN2395 
increased the expression of Nos2 and Tnfα, but not Arg1. ApG-ODN2395 did not show any effect on these genes 
expression. UD: undetermined. Data represents means ± SD of relative values vs control from 3 independent 
experiments. * p < 0.05; * * p < 0.005; * * * p < 0.0005, statistical analysis was performed with one-way ANOVA 
with Dunn’s test for multiple comparisons, while unpaired Student’s t test and Mann-Whitney test for two 
individual comparisons.
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the exact mechanism remains unclear as to how the CpG-ODNs restrain stalk cell status from subsequent tip cell 
formation.
If the TLR9 binding molecule CpG motif is dispensable for anti-angiogenic effect on vascular endothelial cells, 
it is reasonable to assume that TLR9 activation is also non-essential. In vitro results indicate that perturbing TLR9 
signalling in endothelial cells with either chloroquine or siRNA does not impact HUVEC microtube formation 
by ODNs (Fig. 3g,h). The exact binding site of CpG-ODN in endothelial cells remains unclear. It has been deo-
monstrated that TLR9 is retained in the endoplasmic reticulum prior to stimulation and TLR9 bypasses the Golgi 
complex before translocation to endolysosomes where binding to CpG-ODN occurs49. Nevertheless, we observed 
cytoplasmic distribution of ODN2395 within endothelial cells (Supplementary Fig. S5). However, in the corneal 
neovascularisation model treatment with CpG-ODNs attenuated angiogenesis, indicating the participation of an 
elicited innate immune response by CpG in the anti-angiogenic process. To this end, we showed that the effect of 
suppressing corneal neovascularisation by CpG-ODN was diminished in TLR9−/− mice (Fig. 3e,f). The data con-
firms that the anti-angiogenic effect, at least in the cornea, is both PS-backbone and TLR9 dependent. Although 
the role of endothelial cells is essential in angiogenesis, there are multiple cell types taking part in the process50,51, 
The TLR9-independent effect on endothelial cells may contribute to but is not sufficient for angiogenic suppres-
sion without TLR9 activation in the corneal angiogenesis model.
Stabilisation and maturation of the vascular sprout during new vessel formation is accompanied by the 
recruitment of pericytes and macrophages, which involves cellular cross talk in an autocrine and/or paracrine 
manner52,53. Not surprisingly perhaps, but nevertheless not recognised previously, was the significant reduction 
in pericyte migration demonstrated in vitro following CpG treatment (Fig. 5c). Many studies detail the role of 
macrophages in regulating angiogenesis54. However, we show profound preclinical effects of CpG-ODN despite 
the influence of CpG-ODN immune activation34, and as we show, with a macrophage M1 polarization and atten-
uation of endothelial responses. In the absence of macrophages, angiogenesis was suppressed but not augmented 
by CpG-ODN (Fig. 6b–e). Although free clodronate inhibits angiogenesis by suppressing endothelial cell prolifer-
ation55, liposome-encapsulated clodronate has no effect on endothelial or smooth muscle cells56. The paradigm of 
co-existence of inflammation and anti-angiogenesis elicited by CpG-ODN can be favourable in treating tumours 
and now with this data, ocular vascular diseases. Here we showed that the CpG-ODN stimulated macrophages 
inhibit vascular endothelial cell (HUVEC) tube formation (Fig. 6f–h), with further demonstration that CpG, as an 
immune-stimulator, actives TLR9 in macrophages to initiate inflammation, and polarises macrophages to an M1 
anti-angiogenic phenotype57,58 (Fig. 6i–k). This data also converges with the growing evidence that M1 tumour 
associated macrophages are involved in the inhibition of angiogenesis as well as anti-tumour immunity in addi-
tion to their traditional pro-inflammation role59,60. Nevertheless, further experiments are required to confirm the 
interplay of macrophages and endothelial cells in vivo in the presence of CpG-ODN.
In summary, we demonstrate that all three classes of CpG-ODNs have an anti-angiogenic effect on endothelial 
cells, which requires backbone phosphorothioate but not TLR9 signalling. In contrast, CpG motifs and TLR9 
activation are necessary for macrophages polarization to M1 phenotype and further suppression of endothelial 
cell activity to augment the anti-angiogenic responses. Therefore, the suppression of angiogenesis mediated by 
CpG-ODNs modulates both endothelial cells and macrophages through distinct pathways, and provides potential 
therapeutic application in ocular vascular diseases.
Methods
Cell culture and reagents. Primary Human Umbilical Vein Endothelial Cells (HUVEC) (PromoCell, 
Heidelberg, Germany) were cultured in endothelial cell growth medium (EGM, Promocell) to passage 4 or 5 
before being treated with various CpG-ODNs (Supplementary Table S1) (TIB Molbiol, Berlin, Germany). 
Pericytes were immuno-sorted from saphenous vein leftovers of coronary artery bypass graft surgery patients 
as described previously61,62. Bone marrow derived macrophages (BMDM) were prepared from 4–6 weeks old 
C57BL/6 mice as described before63. BMDM cultures were stimulated with IL-4 (20 U/mL) (PeproTech, UK), 
LPS (1 μ g/mL) (Sigma) and CGS-21680 (10 nM) (Sigma). Studies on cells from human subjects complied with 
the principles stated in the “Declaration of Helsinki” and were covered by approval (06/Q2001/197) from the Bath 
Research Ethics Committee.
Animals. Adult (6–10 weeks) B10.RIII, C57BL/6 and B6LY5 mice were bred and housed in University of 
Bristol. Postnatal (P) 4 C57BL/6 mice were bred and housed in UCL central lab. Balb/c mice, aged 6–8 weeks, 
were purchased from Harlan UK Limited (Blackthorn, UK). TLR9 deficient mice backcrossed to C57BL/6 back-
ground, were provided and bred in Zhongshan Ophthalmic Center of Sun Yat-Sen University. The strain of 
neonatal mice was C57BL/6. All the animal experiments were undertaken in both sexes. All procedures were 
conducted under the regulation of the United Kingdom Home Office Animals (Scientific Procedures) Act 1986, 
and were in compliance with the Association for Research in Vision and Ophthalmology (ARVO) statement 
for the use of animals in ophthalmic and vision research. The methods were carried out in accordance with the 
approved University of Bristol institutional guidelines and all experimental protocols under Home Office Project 
Licence 30/3045 and 30/3281 were approved by the University of Bristol Ethical Review Group.
siRNA transfection in HUVECs. A pool of 3 independent small interfering RNA (siRNA) targeting differ-
ent sequences of TLR9 mRNA and their scramble sequences were purchased from Thermo Scientific. HUVECs 
were transfected with siRNA (10 nM) using lipofectamine RNAiMAX (Life Technologies, Invitrogen) accord-
ing to manufacturer’s protocol. The knock-down efficiency was detected by conventional PCR (TLR9, for-
ward: 5-CTACAACCGCATCGTCAAAC-3; reverse: 5-ATCGAGTGAGCGGAAGAAGA-3) and western blot 
(anti-human TLR9, Abcam, Cambridge, UK).
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ELISA. The protein expression of VEGF and sFlt-1 in conditioned media from aortic ring cultures were 
determined by mouse VEGF and sFlt-1 ELISA kits (R&D Systems, Minneapolis, MN, USA) according to the 
manufacturer’s protocols. The absorbance was measured at 450 nm on a microplate reader and VEGF and sFlt1 
concentrations were calculated using linear regression analysis.
Quantitative RT-PCR. Total mRNAs were purified from HUVECs, mouse corneas or BMDM using the 
RNeasy Mini Kit (Qiagen, Hamburg, Germany) as described by the manufacturer protocol. The mRNAs were 
reverse-transcribed using the Reverse Transcription System (Promega, Wisconsin, USA). The two-step qRT-PCR 
SYBR Green method was used to test the gene expressions as listed in supplementary table S2, which were meas-
ured in the same sample and relative ratios of fluorescent intensities of products from each treatment group were 
calculated by stimuli using the 2−ΔΔCt method64.
Western blotting. Protein was extracted from TLR9 siRNA or scrambled RNA transfected HUVECs by 
Cellytic MT buffer (Sigma) according to the manufacture’s protocol. The concentration of protein was deter-
mined using BCA kit (Thermo Scientific). Membranes were incubated with HRP-conjugated secondary antibody 
(Cell signalling, MA, USA). The signals were developed with ECL reagent (Sigma) and captured by an electronic 
imaging system (Konica Minolta). β -actin (Cell signalling) was used as house-keeping control. Each samples 
was loaded as 10 μ g protein in 40 μ L. The quantification was achieved by normalizing each sample to its β -actin 
expression.
HUVEC tube formation and migration assay. P5 HUVECs were seeded on Matrigel (BD Biosciences) 
in endothelial cell basic medium (EBM) with 100 ng/mL VEGF (Sigma) and with or without treatments. Different 
doses of CpG-ODNs or their customized controls were used to treat HUVEC for 24 hours before assessment of 
tube formation. Chloroquine (InvivoGen, France), a lysosomotropic agent that prevents endosomal acidifica-
tion65, was used to treat HUVECs to inhibit TLR9 activation with the stimulation of CpG-ODNs. For the condi-
tioned medium from macrophages, CpG-ODN or ApG-ODN was used to stimulate cells for 8 hours, before the 
supernatant was replaced by fresh medium without stimulation. Following further incubation for 16 h in fresh 
medium, the culture supernatant was collected before adding to HUVECs to access tube formation. The condi-
tioned medium was mixed with HUVECs culture medium as 1:1 ratio for each well. HUVECs were seeded in 
culture-inserts in EBM (Ibidi, Germany). After incubation at 37 °C overnight, all  the inserts were removed before 
adding fresh EBM with or without ODN treatments. Phase contrast photos were taken post treatment by Wide 
field microscope (Leica DMI6000). The whole area of gaps was quantified by ImageJ1.46r (National Institutes of 
Health, USA) and ratio of gap closure was calculated by division of 0 h gap for each time point.
Transwell migration assay. HUVECs were cultured in EBM with or without ODN treatment for 24 hours 
before the supernatant was transferred to the lower chamber of transwell (Corning, UK), while the upper cham-
ber was seeded with human pericytes or BMDM for 16 hours. EBM medium alone was included in lower cham-
ber as negative control. The membranes of the upper chamber were fixed with 4% paraformaldehyde followed by 
staining with DAPI (4′ , 6-diamidino-2-phenylindole) for cell counts. Five fields of photos were randomly taken 
under x20 microscope for each down-side membrane.
Aortic ring assay and choroidal explant assay. Aortic rings were prepared from wild-type B10.RIII 
mice aged 4–6 weeks as previously described66. Aortic rings were embedded in collagen gel (Millipore) before 
being treated with different doses of CpG-ODNs, their customized controls or medium alone from day 0. After 
7 days of treatment, supernatant was collected to determine VEGF and sFlt1 expression by ELISA, while aortic 
rings were fixed for flat mount immunofluorescence. The total number of sprouts were counted under confocal 
microscope. Mouse peripheral choroid-scleral complex was dissected from B10.RIII mice aged 6-8 weeks and cut 
into approximately 1 × 1 mm pieces before being embedded in Matrigel (BD Biosciences) as described before67. 
Phase contrast photos of explants were taken on day 7, and the sprouting areas were quantified using ImageJ 1.46r 
(National Institutes of Health).
Suture induced corneal neovascularization model. Balb/c mice or TLR9−/− mice received 3 inter-
rupted 11-0 Nylon sutures (Mani, Japan) at 1 mm from limbus after anesthesia by intraperitoneal (i.p.) injection 
of Vetelar (ketamine hydrochloride 100 mg/mL, Pfizer, UK) and Rompun (xylazine hydrochloride 20 mg/mL, 
Bayer, UK) mixed with sterile water in the ratio 0.6:1:84. Sub-conjunctival administration of 3 μ L water or ODNs 
was performed on alternate days. The length and volume of outgrowing corneal neovessels were scored under 
surgical and confocal laser scanning microscope on day 7 with scoring system (Supplementary Table S3).
Macrophage depletion. Macrophage depletion in B6LY5 mice was achieved by administration of 
clodronated-liposomes68 (ClodronatedLiposomes.com, Amsterdam, Netherlands). For systemic macrophage 
depletion, 1 mg/200 μ L of clodronate or PBS liposomes was administrated intraperitoneally; whereas for local 
depletion, 0.05 mg/10 μ L clodronate or PBS liposomes were delivered via sub-conjunctival injection on days 3 
and 6. The efficacy of macrophage depletion by clodronate was confirmed by immunohistochemistry staining for 
F4/80+ and CD11b in spleen and eye cryosections. Corneal suturing was performed at day 7 on the clodronate 
treated mice.
Vascularisation of neonatal retina. Mice were given intravitreal injection of either water or CpG-ODN 
(0.4 μ g/0.25 μ L) at postnatal day (P) 4. After 24 h, mice were sacrificed and retinas were dissected for immunofluo-
rescence staining with anti-IB4 (1:100, Sigma). Representative images demonstrate the typical vascular phenotype 
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observed in at least eight retinas. Image quantifications were performed using ImageJ. The number of filopodial 
extensions were quantified at the retina angiogenic front in a minimum of 12 fields (sized 1256 μ m × 957 μ m). 
Vascular progression was measured by defining a straight line from optic disc to the angiogenic front for each 
retina quadrant in a low magnification stereomicroscope pictures. There were 12 measurements for each retina.
Laser-induced choroidal neovascularisation (CNV) Model. The pupils of B10.RIII mice were dilated 
using topical 1% tropicamide (0.5% w/v, Bausch & Lomb, Aubenas, France), before induction of anesthesia. Four 
laser spots were introduced in each eye on the posterior retina using OculightSlx Krypton Red Laser system 
(power 200 mW, duration 75 ms, spot size 75 μ m). Immediately following laser, local administration of Class B 
CpG-ODN1826 (500 μ M in 2 uL dH2O) or vehicle control was performed by intravitreal injection. Mice were 
sacrificed on day 7 post laser. The eyes were collected for immunostaining with biotinylated isolectin IB4 anti-
body (Sigma), followed by staining with Streptavidin-Rhodamine Red X (1:300, Jackson Immuno Research 
Laboratories).
Immunohistochemistry and immunofluorescence. Dissected corneas were fixed in 2% paraformal-
dehyde over night at 4 °C. The cornea whole mounts were co-stained with anti CD31- APC (BD Biosciences) 
and purified rabbit anti mouse LYVE-1 (Abcam) antibodies, followed by secondary goat anti rabbit Alexa Fluor 
488 (Invitrogen). The volume of blood and lymphatic vessels was quantified using Volocity version 6.2.1 software 
(PerkinElmer, Massachusetts, USA). Mouse aortic rings were stained using rat anti-CD31-APC. All Images were 
captured by Leica SP5-AOBS confocal laser microscope. Mice eyes were snap frozen in OCT (optical cutting 
temperature compound, Thermo, Waltham, MA, USA). Cryosections were fixed in acetone and immunostained 
with rat anti-mouse biotinylated CD11b (at dilution 1:100, BD Phamingen), and F4/80 (at dilution 1:100, BD 
Biosciences) antibodies in conjunction with the HRP conjugated StrepABC kit (Vector Labs, Burlingame, CA) 
and DAB substrate kit (Vector Labs). Mouse IgG isotype was used as a negative control at dilution 1:100 (BD 
Biosciences).
Statistics. Results are therefore presented as means ± standard deviation (S.D.). Comparisons of two indi-
vidual experimental groups were performed by unpaired Student’s t test and Mann-Whitney test. For multiple 
comparisons, nonparametric analysis was performed using one way ANOVA test with Dunn’s test. All the analysis 
was performed using GraphPad Prism 6 (GraphPad Software, version 6.01, La Jolla, USA). Two-tailed tests were 
used throughout. The significant differences were considered at P ≤ 0.05.
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